Direct Selective Laser Trabeculoplasty for Glaucoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a laser procedure called Direct Selective Laser Trabeculoplasty (DSLT) to determine its effectiveness in lowering eye pressure in individuals with primary open angle glaucoma. The main focus is to compare eye pressure before treatment and six months after, without any glaucoma medications. The trial seeks adult participants of Black African descent diagnosed with mild to moderate primary open angle glaucoma who are not currently using any eye pressure-lowering medications. As an unphased study, this trial offers a unique opportunity to contribute to innovative research that could lead to new treatment options for glaucoma.
Will I have to stop taking my current medications?
Yes, you will need to stop taking your current glaucoma medications before the procedure, as the trial requires participants to have a 'washed out' eye pressure, meaning no glaucoma medications at the time of the procedure.
What prior data suggests that Direct Selective Laser Trabeculoplasty is safe for treating glaucoma?
A previous study demonstrated that Direct Selective Laser Trabeculoplasty (DSLT) is safe for patients. DSLT is a laser treatment used to lower eye pressure in people with glaucoma. Research has shown that most patients tolerate DSLT well. These studies have reported no major safety issues. Some patients might experience mild discomfort or temporary redness in the eye after the procedure, but these effects usually resolve quickly. Overall, DSLT is considered a safe option for reducing eye pressure in glaucoma patients.12345
Why are researchers excited about this trial?
Direct Selective Laser Trabeculoplasty (DSLT) is unique because it offers a non-invasive laser treatment that specifically targets the trabecular meshwork, the area responsible for draining fluid from the eye. Unlike traditional treatments for glaucoma, such as eye drops or surgery, DSLT aims to enhance fluid drainage without the need for incisions or ongoing medication use. Researchers are excited about this treatment because it has the potential to lower eye pressure effectively and safely, providing a promising alternative for patients seeking less invasive options.
What evidence suggests that Direct Selective Laser Trabeculoplasty is effective for lowering eye pressure in glaucoma?
Research has shown that Direct Selective Laser Trabeculoplasty (DSLT), the treatment under study in this trial, can effectively lower eye pressure in people with glaucoma. Studies indicate that DSLT can reduce intraocular pressure by more than 20%. Lowering eye pressure is crucial because it helps slow glaucoma progression and prevents vision loss. DSLT resembles another procedure, Selective Laser Trabeculoplasty (SLT), known for its safety and effectiveness. Unlike SLT, DSLT does not require a contact lens on the eye, potentially offering more comfort for patients. These promising findings support DSLT's potential as a treatment for glaucoma.12367
Are You a Good Fit for This Trial?
This trial is for adult, non-Caucasian patients with primary open-angle glaucoma. It's designed to see if a procedure called Direct Selective Laser Trabeculoplasty (DSLT) can lower eye pressure. Participants will need to have their vision and eye pressure checked several times after the procedure.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo the Direct Selective Laser Trabeculoplasty (DSLT) procedure in one or both eyes
Follow-up
Participants visit the clinic to have their vision and eye pressure measured
What Are the Treatments Tested in This Trial?
Interventions
- Direct Selective Laser Trabeculoplasty (DSLT)
Trial Overview
The study tests the effectiveness of DSLT in reducing eye pressure in glaucoma patients. The key measure is comparing participants' eye pressures before and six months after undergoing DSLT, without any glaucoma medications influencing results.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
Select Eye Care
Lead Sponsor
Citations
First results of direct selective laser trabeculoplasty for the ...
Selective laser trabeculoplasty (SLT) is an intraocular pressure (IOP) lowering procedure recognised to be safe and effective in patients with ...
Randomized Noninferiority Trial of Direct Selective Laser ...
Effective glaucoma treatment is limited by nonadherence to medications and access to selective laser trabeculoplasty (SLT). The GLAUrious study compared ...
NCT07076303 | A Prospective Study on the Efficacy of ...
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction ...
Direct Selective Laser Trabeculoplasty
In 2019, for the first time, high-quality longitudinal data showed a tangible benefit to using selective laser trabeculoplasty (SLT) as primary therapy for ...
DSLT: The Future of Glaucoma Treatment
Unlike conventional SLT (Selective Laser Trabeculoplasty), which uses a contact lens on the eye to target the drainage angle with a slit lamp, ...
This Issue at a Glance
The researchers conclude that DSLT provided clinically meaningful IOP reductions at 6 months even if it was not as effective as SLT, and they suggest that it ...
Voyager™ DSLT Laser Treatment for Glaucoma | Alcon US
Indications: Voyager™ DSLT is indicated for use in selective laser trabeculoplasty (SLT). Contraindications: Use of the Voyager™ DSLT device is contraindicated ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.